Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia in Chronic Kidney Disease: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2034

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$17995
Buy Report Download FREE Resources

Published: November 24, 2025 Report Code: GDHCOA057-ST

Select Item

Chronic kidney disease market analysis covering hyperparathyroidism, hyperphosphatemia, and hyperkalemia. Explore epidemiology, treatment trends, pipeline drugs, competitive benchmarking, and 7MM forecasts through 2034. This report deliverables include a PowerPoint report and an Excel-based forecast model.

Understand the Future of CKD-Related Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia Treatment Markets

Chronic kidney disease (CKD) continues to create significant clinical and commercial challenges worldwide. This report helps you understand how hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) are evolving within the CKD treatment landscape.

You will gain insight into disease burden, treatment patterns, and market dynamics across the seven major markets (7MM): the US, France, Germany, Italy, Spain, the UK, and Japan.

Moreover, the report explores how changing patient demographics, unmet clinical needs, and emerging therapies may influence market growth through 2034.

As a result, you can better assess future opportunities in CKD supportive care and nephrology therapeutics.

Report Value Proposition – Why This Matters for You

This report goes beyond market sizing. It helps you evaluate where commercial opportunities may emerge and how competitive dynamics are shifting.

You can use this report to:

  • Identify growth opportunities across CKD-HPT, HP, and HK therapeutics
  • Benchmark against global leaders in nephrology and renal care
  • Assess pipeline strength and emerging mechanisms of action
  • Support licensing, partnering, and investment decisions
  • Evaluate unmet clinical and environmental needs across the 7MM
  • Develop evidence-based commercial and market access strategies

Additionally, the report combines epidemiology, forecasting, pipeline analysis, and competitive intelligence in a single decision-support resource.

Therefore, you can move from fragmented market data to actionable strategic insight more efficiently.

Key Insights Into the CKD Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia Markets

The report provides detailed analysis across the major CKD-related comorbidity markets:

  • Diagnosed prevalent cases of CKD-HPT, HP, and HK are expected to increase across the 7MM over the forecast period
  • Phosphate binders, calcimimetics, and potassium binders remain the mainstay therapies
  • Significant unmet needs continue to create opportunities for innovation and differentiation
  • Combined market sales are projected to grow from $2.6 billion in 2024 to $4.0 billion by 2034
  • Late-stage pipeline candidates may reshape future treatment pathways

Furthermore, the report analyzes the impact of clinical trial activity, emerging therapeutic mechanisms, and evolving standards of care.

Scope

What You Will Learn 

The report delivers a comprehensive assessment of the CKD-HPT, HP, and HK therapeutics market, including:

  • CKD disease overview, symptoms, diagnosis, and disease management

  • Epidemiology analysis across the 7MM

  • Annualized market revenue forecasts through 2034

  • Treatment usage patterns and annual cost of therapy analysis

  • Strategic competitor assessment and market characterization

  • Clinical trial mapping and pipeline analysis

  • Emerging mechanisms of action and late-stage candidates

  • Analysis of market drivers, restraints, and future challenges

Additionally, the report includes a detailed Excel-based forecast model to support scenario planning and market evaluation.

Target Buyers for This Report

This report is designed for decision-makers responsible for growth, innovation, and market strategy, including:

  • Heads of Commercial Strategy

  • Nephrology Franchise Leaders

  • Business Development and Licensing Teams

  • Pharmaceutical Market Intelligence Professionals

  • Healthcare Investors and Equity Analysts

  • Competitive Intelligence Teams

  • Clinical Development Leaders

  • Corporate Strategy Executives

If you are evaluating opportunities in CKD therapeutics or renal disease management, this report can support more informed decisions.

How Companies Use This Report

Organizations across pharmaceuticals, biotech, healthcare, and investment sectors can apply this report in practical ways:

  • Pharmaceutical companies: Companies such as AstraZeneca and Amgen may use the report to evaluate market expansion opportunities, competitive risks, and commercialization strategies.

  • Biotech innovators: Firms like Ardelyx and Akebia can leverage pipeline intelligence and unmet-needs analysis to prioritize R&D investments.

  • Investors and private equity firms: Assess long-term market growth, forecasted revenues, and emerging therapeutic platforms across nephrology.

  • Business development and licensing teams: Identify companies with promising late-stage assets and evaluate partnership or acquisition opportunities.

  • Commercial strategy and market access teams: Understand treatment usage patterns, annual therapy costs, and future reimbursement considerations across the 7MM.

Consequently, the report helps transform market intelligence into actionable business strategy.

Reasons to Buy

Report deliverables include a PowerPoint report and an interactive Excel-based forecast model.

Benchmark Against Global Leaders in Nephrology Therapeutics

Understanding competitor positioning is critical in a changing CKD market. Therefore, this report helps you benchmark pipelines, commercial strategies, and innovation activity against leading companies.

Key companies analyzed include:

  • Amgen

  • AstraZeneca

  • Ardelyx

  • Akebia

  • Kyowa Kirin Co

  • CSL

The report also profiles emerging innovators and late-stage developers that may influence future market competition.

As a result, you can better evaluate competitive threats, partnership targets, and whitespace opportunities.

Built on Trusted Data and Expert Analysis

This report is powered by GlobalData’s proprietary healthcare intelligence and analyst expertise.

  • Trusted by Fortune 500 companies and leading government organizations

  • Backed by analysts with deep expertise in pharmaceuticals and healthcare markets

  • Developed using rigorous forecasting methodologies and epidemiology models

  • Delivered with both a PowerPoint report and Excel-based forecast model

Therefore, you can integrate the findings directly into forecasting, strategy, and investment workflows.

H2: Act Now to Stay Ahead in the CKD Therapeutics Market

The CKD supportive care landscape is evolving steadily. However, increasing disease prevalence and persistent unmet needs continue to create strategic opportunities.

This report helps you understand where growth may emerge, which companies are advancing innovation, and how the competitive environment is changing across the 7MM.

Therefore, if you are assessing opportunities in hyperparathyroidism, hyperphosphatemia, or hyperkalemia therapeutics, timely market intelligence can provide an important advantage.

 

Amgen
Ono Pharmaceuticals
Kyowa Kirin Co
Opko Health
CSL
Akebia
Torii Pharmaceutical
AstraZeneca
Ardelyx
Sanwa Kagaku Kenkyusho
Pathalys Pharma
Shanghai Alebund Pharmaceuticals
Taisho Pharmaceutical

Table of Contents

1. Preface

1.1. Contents

1.2. Abbreviations

1.3. Related Reports

2. Executive Summary

3. Disease Overview

3.1. Overview of CKD

3.2. Classification of CKD

3.3. Etiology & Pathophysiology of CKD-HPT, HP, and HK

3.4. CKD- HPT, HP, and HK SWOT Analysis

4. Epidemiology

4.1. Diagnosed Prevalent Cases of CKD

4.2. Age-Specific Trends in Diagnosed Prevalent Cases of CKD

4.3. Sex-Specific Diagnosed Prevalent Cases of CKD

4.4. Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence

4.5. Diagnosed Prevalent Cases of CKD with HPT

4.6. Diagnosed Prevalent Cases of CKD with HP

4.7. Diagnosed Prevalent Cases of CKD with HK

4.8. Total Prevalent Cases of CKD

4.9. Total Prevalent Cases of CKD by Stage

4.10. Sources and Methodology: Total Prevalent Cases of CKD by Stage

4.11. Sources and Methodology: Diagnosed Prevalent Cases of CKD

4.12. Sources and Methodology: Diagnosed Prevalent Cases of CKD by Stage

4.13. Sources and Methodology: Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence

4.14. Sources and Methodology: Diagnosed Prevalent Cases of CKD with HPT, HP, and HK Among Dialysis-Dependent and Non-dialysis-Dependent CKD Cases

4.15. Sources and Methodology: Total Prevalent Cases of CKD

4.16. Sources and Methodology – Diagnosed Prevalent Cases of CKD with HPT Among Dialysis-Dependent and Non-Dialysis-Dependent CKD Cases

4.17. Sources and Methodology – Diagnosed Prevalent Cases of CKD with HP Among Dialysis-Dependent and Non-dialysis-Dependent CKD Cases

4.18. Sources and Methodology – Diagnosed Prevalent Cases of CKD with HK Among Dialysis-Dependent and Non-Dialysis-Dependent CKD Cases

5. Current Treatment Options

5.1. Treatment Paradigm

5.2. Current Treatment Options

5.3. Product Profile: sevelamer carbonate/sevelamer hydrochloride

5.4. Product Profile: lanthanum carbonate

5.5. Product Profile: Velphoro (sucroferric oxyhydroxide)

5.6. Product Profile: Auryxia (ferric citrate)

5.7. Product Profile: cinacalcet

5.8. Product Profile: Auryxia (ferric citrate)

5.9. Product Profile: Parsabiv (etelcalcetide hydrochloride)

5.10. Product Profile: Orkedia (evocalcet)

5.11. Product Profile: Rayaldee (calcifediol ER)

5.12. Product Profile: Veltassa (patiromer sorbitex calcium)

5.13. Product Profile: Lokelma (sodium zirconium cyclosilicate)

5.14. Product Profile: Xphozah/Phozevel (tenapanor hydrochloride)

6. Unmet Needs and Opportunities

6.1. Unmet Needs in CKD- HPT, HP, and HK

6.2. Poor Medication Adherence and High Pill Burden

6.3. Drug Cost and Market Access

6.4. Improving Tolerability and Side-Effect Profile

6.5. Optimal Management of HK Treatments

7. R&D Strategies

7.1. Trends in Clinical Trial Design for CKD- HPT, HP, and HK

7.2. Trends in Deal-Making in CKD- HPT, HP, and HK

8. Pipeline Assessment

8.1. CKD- HPT, HP, and HK Pipeline Overview

8.2. Late-Stage Pipeline Agents for CKD- HPT, HP, and HK

8.3. Product Profile: upacicalcet sodium

8.4. Product Profile: AP-301

8.5. Product Profile: TS-172

8.6. CKD- HPT, HP, and HK Clinical Trials (Phase II/III) Overview

9. Market Outlook

9.1. CKD- HPT, HP, and HK Market Outlook

9.2. CKD- HPT, HP, and HK Market Forecast

9.3. Market Drivers and Barriers

10. Appendix

10.1. Primary Research – KOL Information

10.2. About the Authors

11. Contact Us

Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia in Chronic Kidney Disease: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2034 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

Most Popular
$35,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia in Chronic Kidney Disease: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2034 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia in Chronic Kidney Disease: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2034 in real time.

  • Access a live Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia in Chronic Kidney Disease: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2034 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more